Rockefeller Capital Management
SLN

Rockefeller Capital Management’s Silence Therapeutics SLN Stock Holding History

Rockefeller Capital Management’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$237 Hold
45
– – ﹤0.01% 4596
2025
Q4 		$274 Hold
45
– – ﹤0.01% 4574
2025
Q3 		$234 Buy
+45
New +$250 ﹤0.01% 4340

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Rockefeller Capital Management's SLN Position: Q1 2026 in Review

Rockefeller Capital Management held its Silence Therapeutics (SLN) position steady in Q1 2026 at 45 shares worth $237. The position accounts for ﹤0.01% of the portfolio, ranked #4596.

Rockefeller Capital Management first reported a position in SLN in Q3 2025 and has held it in 3 quarters since. The position peaked at $274 in Q4 2025. 56 funds tracked by Wall St. Rank hold SLN as of Q1 2026.

  • Rockefeller Capital Management held 45 shares of Silence Therapeutics worth $237 as of Q1 2026.
  • Rockefeller Capital Management left its Silence Therapeutics share count unchanged in Q1 2026.
  • Silence Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #4596 holding.
  • Rockefeller Capital Management first reported a position in Silence Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Rockefeller Capital Management's Silence Therapeutics position peaked at $274 in Q4 2025.
  • 56 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.